单次立体定向部分乳腺照射治疗早期乳腺癌的多中心Ⅰ期剂量递增试验初步结果
这项多中心Ⅰ期剂量递增试验纳入30例0–Ⅱ期、肿瘤<3 cm且接受肿块切除术的乳腺原位或浸润癌女性,单次给予22.5、26.5或30 Gy机器人立体定向部分乳腺照射。结果未达最大耐受剂量,无急性≥3级治疗相关毒性,仅2例迟发3级毒性,4例(13.8%)出现脂肪坏死,无疾病复发,美容评分较基线无显著下降。
要点
- 单次S-PBI可安全递增至30 Gy,未达到最大耐受剂量。
- 无急性≥3级治疗相关毒性,仅2例迟发3级毒性。
- 各剂量组美容评分自基线至12或24个月无显著下降,无复发病例。
核心结论
- 单次立体定向部分乳腺照射可安全将剂量递增至30 Gy,毒性低且美容未见较基线受损。
研究设计与样本
- 多中心前瞻性Ⅰ期单次S-PBI剂量递增试验,纳入30例0、Ⅰ或Ⅱ期肿瘤<3 cm且行肿块切除术的乳腺原位或浸润癌女性。
- 患者分别接受单次22.5、26.5或30 Gy机器人立体定向放疗,主要终点为在不超最大耐受剂量下达到30 Gy肿瘤杀灭剂量。
主要发现
- 22.5、26.5、30 Gy组分别治疗11、8、10例,中位随访分别为47.9、25.1、16.2个月。
- 无患者发生急性(<90天)≥3级治疗相关毒性,未达到最大耐受剂量,有2例迟发3级毒性。
- 全部3个队列共4例(13.8%)出现脂肪坏死,与其他PBI试验相比结果有利。
- 患者或医生报告的总体美容评分自基线至12个月或24个月随访,各剂量队列均无统计学显著美容损害。
- 无疾病复发报告。
关键数值与推荐
- 单次S-PBI剂量递增至30 Gy未超过最大耐受剂量。
- 急性<90天≥3级治疗相关毒性为0例,迟发3级毒性2例,脂肪坏死4例(13.8%)。
临床怎么用
- 早期乳腺癌肿块切除术后可考虑单次S-PBI,剂量可递增至30 Gy且毒性低、美容可接受。
- 需关注迟发3级毒性和脂肪坏死,并持续随访美容与复发结局。
局限性
- 为Ⅰ期剂量递增试验,样本量30例,各剂量组随访时间不等且部分较短。
- 未设对照组,长期美容、复发与生存结局需更长时间随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We report on our early experience of our prospective multicenter phase 1 dose- escalation study of single-fraction stereotactic partial breast irradiation (S-PBI) for early stage breast cancer after partial mastectomy using a robotic stereotactic radiation system. METHODS AND MATERIALS: Thirty women with in situ or invasive breast cancer stage 0, I, or II with tumor size <3 cm treated with lumpectomy were enrolled in this phase 1 single-fraction S-PBI dose-escalation trial. Women received either 22.5, 26.5, or 30 Gy in a single fraction using a robotic stereotactic radiation system. The primary outcome was to reach tumoricidal dose of 30 Gy in a single fraction to the lumpectomy cavity without exceeding the maximum tolerated dose. Secondary outcomes were to determine dose-limiting toxicity and cosmesis. Tertiary goals were ipsilateral breast recurrence rate, distant disease-free interval, recurrence-free survival, and overall survival. RESULTS: From June 2016 to January 2021, 11, 8, and 10 patients were treated to doses of 22.5, 26.5, or 30 Gy in a single fraction, respectively, with median follow-up being 47.9, 25.1, and 16.2 months. No patients experienced acute (<90 days) grade 3 or higher treatment-related toxicity, and maximum tolerated dose was not reached. There were 2 delayed grade 3 toxicities. Four patients (13.8%) developed fat necrosis across all 3 cohorts, which compares favorably with results from other PBI trials. No dose cohort had a statistically significant cosmetic detriment from baseline to 12 months or 24 months follow-up by patient- or physician-reported global cosmetic scores. There were no reports of disease recurrence. CONCLUSIONS: This phase 1 trial demonstrates that S-PBI can be used to safely escalate dose to 30 Gy in a single fraction with low toxicity and without detriment in cosmesis relative to baseline.
引用
- Rahimi A, Simmons A, Kim DN, et al. Preliminary Results of Multi-Institutional Phase 1 Dose Escalation Trial Using Single-Fraction Stereotactic Partial Breast Irradiation for Early Stage Breast Cancer. Int J Radiat Oncol Biol Phys. 2021. PMID: 34710523. doi:10.1016/j.ijrobp.2021.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。